Dyslipidemia - Competitive Landscape in 2021
Summary
This reports provides a data-driven overview of the current and future competitive landscape in dyslipidemia therapeutics.
In dyslipidemia 3 hydroxy 3 methylglutaryl coenzyme a (HMG CoA) reductase is a major focus of drug developers. There are 155 drugs in the pipeline with 74% molecules present in early stage. Mid-sized Pharma dominates R&D in this indication. The increasing prevalence and preference for newer expensive therapies will drive the market's growth, but delayed diagnosis, low compliance rate, and high preference for low-cost generic products are likely to limit market growth.
GlobalData’s Dyslipidemia - Competitive Landscape in 2021 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Scope
Components of the report include -
- Disease epidemiology
- Marketed drugs assessment
- Pipeline drugs assessment
- Clinical trials assessment
- Commercial assessment
- Social media overview
- Digital marketing overview
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global dyslipidemia market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global dyslipidemia market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
- 1 Preface
- 1.1 Table of Contents
- 1.2 Abbreviations
- 1.3 Related Reports
- 1.4 Upcoming Related Reports
- 2 Executive Summary
- 2.1 Key Findings
- 2.2 Key Events
- 3 Introduction
- 3.1 Report Scope
- 3.2 Disease Overview Epidemiology Overview
- 3.3 Epidemiology
- 4 Marketed Drugs Assessment
- 4.1 Marketed Drugs Overview
- 4.2 Marketed Drug Profiles
- 5 Pipeline Assessment
- 5.1 Pipeline Overview
- 5.2 Pipeline Breakdown by Region
- 5.3 Pipeline Breakdown by Molecule Type and Target
- 5.4 Drug Review Designations
- 5.5 Phase Transition Success Rates
- 5.6 Likelihood of Approval
- 6 Clinical Trial Assessment
- 6.1 Clinical Trials Overview by Phase
- 6.2 Overview by Region
- 6.4 Therapy Area Perspective
- 6.4 Leading Sponsors
- 6.5 Enrollment Analytics
- 6.6 Feasibility Analysis
- 7 Commercial Assessment
- 7.1 Upcoming Market Catalysts
- 8 Social Media and Digital Marketing
- 8.1 Key Twitter Chatter
- 8.2 Top Branded Websites
- 8.3 Trust Flow and Citation Flow
- 9 Appendix
- 9.1 Methodology
- 9.2 About the Authors
- 9.3 About GlobalData
- 9.4 Contact Us
- 9.5 Disclaimer
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook